Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fitusiran - Alnylam Pharmaceuticals/Sanofi

Drug Profile

Fitusiran - Alnylam Pharmaceuticals/Sanofi

Alternative Names: ALN-AT3; ALN-AT3SC; SAR-439774

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Sanofi
  • Class Antihaemorrhagics; Drug conjugates; Small interfering RNA
  • Mechanism of Action Antithrombin III expression inhibitors; Haemostasis stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A; Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A; Haemophilia B

Most Recent Events

  • 01 Mar 2024 Phase-I clinical trials in Haemophilia A (Treatment-experienced) in Taiwan (SC) (NCT06145373)
  • 30 Oct 2023 Interim safety and efficacy data from the phase III ATLAS-OLE trial in haemophilia released by Sanofi
  • 27 Oct 2023 Sanofi plans to submit regulatory applications to the US FDA for Haemophilia A and Haemophilia B in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top